Contribute Try STAT+ Today

It’s counterintuitive, but catching cancer early isn’t always for the best. And the coronavirus pandemic might leave lessons for future cancer screening in its wake.

Cancer diagnoses fell off a cliff last spring, when health care was buckling under the first Covid-19 surge and patients steered clear of regular checkups. A precipitous drop in healthy people undergoing colonoscopies, mammograms, or other cancer screening tests so alarmed Ned Sharpless, director of the National Cancer Institute, that he warned in August of turning one public health crisis into many others. His concern drew power from models predicting a combined 10,000 excess deaths from breast and colorectal cancer over the next 10 years if patients continued to miss screening. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.